Basic principles, applications in oncology and improved selectivity of photodynamic therapy

Anticancer Research

Volumn 23, Issue 1 B, 2003, Pages 505-522

  Vrouenraets, Maarten B ^a,c   Visser, Gerard W M ^b   Snow, Gordon B ^a   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Advanced delivery; Clinical photodynamic therapy; Photodynamic therapy; Photosensitizer; Tumor selectivity

Indexed keywords

3 TETRAHYDROXYPHENYLCHLORIN; ACHIDINE; ALUMINUM CHLORIDE PHTHALOCYANINE; AMINOLEVULINIC ACID; BCG VACCINE; CREMOPHOR; DIPALMITOYLPHOSPHATIDYLCHOLINE; EOSIN; EPIDERMAL GROWTH FACTOR; GERMANIUM OCTABUTOXYPHTHALOCYANINE; HEMATOPORPHYRIN DERIVATIVE; INSULIN; LIPOSOME; MACROGOL; MESOCHLORIN E6; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE ALUMINUM; PHTHALOCYANINE DERIVATIVE; PHTHALOCYANINE ZINC; POLYLYSINE CHLORIN E6; POLYMER; POLYVINYL ALCOHOL; TALAPORFIN; TEMOPORFIN; TIN CHLORIN E6; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

BASAL CELL CARCINOMA; BLADDER CANCER; BRAIN TUMOR; BREAST CANCER; BURN; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; CYTOTOXICITY; DRUG APPROVAL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; HEAD CANCER; HISTORY OF MEDICINE; HUMAN; INTESTINE PERFORATION; LUNG CANCER; MESOTHELIOMA; MICELLE; NECK CANCER; ONCOLOGY; PERITONEUM CANCER; PHOTOCHEMISTRY; PHOTODYNAMIC THERAPY; PHOTODYNAMICS; PHOTOSENSITIVITY DISORDER; PHOTOTOXICITY; PRIORITY JOURNAL; REVIEW; ULTRAVIOLET RADIATION;

ANIMALS; HUMANS; NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 0037231489     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Raab O: On the effect of fluorescent substances on infusoria. Z Biol 39: 524-546, 1900.
2. Jodlbauer A and von Tappeiner H: On the participation of oxygen in the photodynamic effect of fluorescent substances. Münch Med Wochenschr 52: 1139-1141, 1904.
3. Jesionek A and von Tappeiner H: On the treatment of skin cancers with fluorescent substances. Arch Klin Med 82: 223-227, 1905.
4. Policard A: Studies of experimental tumours under Wood's light. Comp Rend Soc Biol 91: 1423-1428, 1924.
5. Auler H and Banzer G: Investigations on the role of porphyrins in tumour-bearing humans and animals. Z Krebsforsch 53: 65-68, 1942.
6. Lipson RL and Baldes EJ: The photodynamic properties of a particular haematoporphyrin derivative. Arch Dermatol 82: 508-516, 1960.
7. Moan J and Berg K: The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 53: 549-553, 1991.
8. Nilsson R, Swanbeck G and Wennersten G: Primary mechanisms of erythrocyte photolysis induced by biological sensitizers and phototoxic drugs. Photochem Photobiol 22: 183-186, 1975
9. Shulok JR, Wade MH and Lin CW: Subcellular localization of hematoporphyrin derivative in bladder tumor cells in culture. Photochem Photobiol 51: 451-457, 1990.
10. Wilson BC, Olivo M and Singh G: Subcellular localization of Photofrin® and aminolevulinic acid and photodynamic cross-resistance in vitro in radiation-induced fibrosarcoma cells sensitive or resistant to Photofrin-mediated photodynamic therapy. Photochem Photobiol 65: 166-176, 1997.
11. Woodburn KW, Vardaxis NJ, Hill JS, Kaye AH and Phillips DR: Subcellular localization of porphyriris using confocal laser scanning microscopy. Photochem Photobiol 54: 725-732, 1991.
12. Woodburn KW, Vardaxis NJ, Hill JS, Kaye AH, Reiss JA and Phillips DR: Evaluation of porphyrin characteristics required for photodynamic therapy. Photochem Photobiol 55: 697-704, 1992.
13. Chiu SM, Evans HH, Lam M, Nieminen AL and Oleinick NL: Phthalocyanine 4 photodynamic therapy-induced apoptosis of mouse L5178Y-R cells results from a delayed but extensive release of cytochrome c from mitochondria. Cancer Lett 165: 51-58, 2001.
14. Fabris C, Valduga G, Miotto G, Borsetto L, Jori G, Garbisa S and Reddi E: Photosensitization with zinc (II) phthalocyanine as a switch in the decision between apoptosis and necrosis. Cancer Res 61: 7495-7500, 2001.
15. Ma L, Moan J and Berg K: Evaluation of a new photosensitizer, meso-tetra-hydroxyphenyl-chlorin, for use in photodynamic therapy: a comparison of its photobiological properties with those of two other photosensitizers. Int J Cancer 57: 883-888, 1994.
16. Chen JY, Mak NK, Wen JM, Leung WN, Chen SC, Fung MC and Cheung NH: A comparison of the photodynamic effects of temoporfin (mTHPC) and MC540 on leukemia cells: efficacy and apoptosis. Photochem Photobiol 68: 545-554, 1998.
17. Melnikova VO, Bezdetnaya LN, Bour C, Festor E, Gramain MP, Merlin JL, Potapenko AY and Guillemin F: Subcellular localization of meta-tetra(hydroxyphenyl) chlorin in human tumor cells subjected to photodynamic treatment. J Photochem Photobiol B Biol 49: 96-103, 1999.
18. Yow CMN, Chen JY, Mak NK, Cheung NH and Leung AWN: Cellular uptake, subcellular localization and photodamaging effect of Temoporfin (mTHPC) in nasopharyngeal carcinoma cells: comparison with hematoporphyrin derivative. Cancer Lett 157: 123-131, 2000.
19. Ramakrishnan N, Oleinick NL, Clay ME, Horng MF, Antunez AR and Evans HH: DNA lesions and DNA degradation in mouse lymphoma L5178Y cells after photodynamic treatment sensitized by chloroaluminium phthalocyanine. Photochem Photobiol 50: 373-378, 1989.
20. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J and Peng Q: Photodynamic therapy. J Natl Cancer Inst 90: 889-905, 1998.
21. Kessel D: Determinants of photosensitization by purpurins. Photochem Photobiol 50: 169-174, 1989.
22. Fingar VH, Wieman TJ and Haydon PS: The effects of thrombocytopenia on vessel stasis and macromolecular leakage after photodynamic therapy using Photofrin. Photochem Photobiol 66: 513-517, 1997.
23. e6 on vessel constriction, vessel leakage, and tumor response. Cancer Res 54: 5374-5379, 1994.
24. Fingar VH, Wieman TJ and Karavolos PS: The effects of photodynamic therapy using differently substituted zinc phthalocyanines on vessel constriction, vessel leakage, and tumor response. Photochem Photobiol 58: 251-258, 1993.
25. Krosl G, Korbelik M and Dougherty GJ: Induction of immune cell infiltration into murine SCCVII tumour by Photofrin-based photodynamic therapy. Br J Cancer 71: 549-555, 1995.
26. Lipson RL, Baldes EJ and Olsen AM: The use of a derivative of haematoporphyrin in tumor detection. J Natl Cancer Inst 26: 1-11, 1961.
27. Dougherty TJ, Grindey GB, Fiel R, Weishaupt KR and Boyle DG: Photoradiation therapy. II. Cure of animal tumours with hematoporphyrin and light. J Natl Cancer Inst 55: 115-119, 1975.
28. Kelly JF, Snell ME and Berenbaum MC: Photodynamic destruction of human bladder carcinoma. Br J Cancer 31: 237-244, 1975.
29. Berenbaum MC, Bonnett R and Scourides PA: In vivo biological activity of the components of haematoporphyrin derivative. Br J Cancer 45: 571-581, 1982.
30. Lightdale CJ, Heier SK, Marcon NE, McCaughan JS Jr, Gerdes H, Overholt BF, Sivak MV Jr, Stiegmann GV and Nava HR: Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd: YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest Endosc 42: 507-512, 1995.
31. McCaughan JS, Williams TE and Bethel BH: Photodynamic therapy of endobronchial tumors. Lasers Surg Med 6: 336-345, 1986.
32. Orenstein A, Kostenich G, Roitman L, Shechtman Y, Kopolovic Y, Ehrenberg B and Malik Z: A comparative study of tissue distribution and photodynamic therapy selectivity of chlorin e6, Photofrin II and ALA-induced protoporphyrin IX in a colon carcinoma model. Br J Cancer 73: 937-944, 1996.
33. Bonnett R, White RD, Winfield UJ and Berenbaum MC: Hydroporphyrins of the meso-tetra(hydroxyphenyl) porphyrin series as tumour photosensitizers. Biochem J 261: 277-280, 1989.
34. Berenbaum MC, Bonnett R, Chevretton EB, Akande-Adebakin SL and Ruston M: Selectivity of meso-tetra(hydroxyphenyl)porphyrins and chlorins and of Photofrin II in causing photodamage in tumour, skin, muscle and bladder. The concept of cost-benefit in analysing the results. Lasers Med Sci 8: 235-243, 1993.
35. Ronn AM, Nouri M, Lofgren LA, Steinberg BM, Westerborn A, Windahl T, Shikowitz MJ and Abramson AL: Human tissue levels and plasma pharmacokinetics of Temoporfin (Foscan®, mTHPC). Lasers Med Sci 11: 267-272, 1996.
36. Hettiaratchy S, Clarke J, Taubel J and Besa C: Burns after photodynamic therapy. BMJ 320: 1245, 2000.
37. Bryce R: Drug point gives misleading impression of incidence of burns with temoporfin (Foscan). BMJ 320: 1731, 2000.
38. e6 in the photodynamic therapy of malignant tumors. J Photochem Photobiol B Biol 22: 211-217, 1994.
39. Ambroz M, Beeby A, MacRobert AJ, Simpson MSC, Svensen RK and Phillips D: Preparative, analytical and fluorescence spectroscopic studies of sulphonated aluminum phthalocyanine photosensitizers. J Photochem Photobiol B Biol 9: 87-95, 1991.
40. Berg K, Bommer JC and Moan J: Evaluation of sulfonated aluminum phthalocyanines for use in photochemotherapy. A study on the relative efficiencies of photoinactivation. Photochem Photobiol 49: 587-594, 1989.
41. Paquette B, Boyle RW, Ali H, MacLennan AH, Truscott TG and van Lier JE: Sulfonated phthalimidomethyl aluminum phthalocyanine: The effect of hydrophobic substituents on the in vitro phototoxicity of phthalocyanines. Photochem Photobiol 53: 323-327, 1991.
42. Boyle RW, Paquette B and van Lier JE: Biological activities of phthalocyanines XIV. Effect of hydrophobic phthalimidomethyl groups on the in vivo phototoxicity and mechanism of photodynamic action of sulphonated aluminium phthalocyanines. Br J Cancer 65: 813-817, 1992.
43. Pandey RK, Shiau FY, Sumlin AB, Dougherty TJ and Smith KM: Structure/activity relationships among photosensitizers related to pheophorbides and bacteriopheophorbides. Bioorg Med Chem Lett 2: 491-496, 1992.
44. El-Sharabasy MM, El-Waseef AM, Hafez MM and Salim SA: Porphyrin metabolism in some malignant diseases. Br J Cancer 65: 409-412, 1992.
45. Leibovici L, Schoenfeld N, Yehoshua HA, Mamet R, Rakowsky E, Shindel A and Atsmon A: Activity of porphobilinogen deaminase in peripheral blood mononuclear cells of patients with metastatic cancer. Cancer 62: 2297-2300, 1998.
46. Peng Q, Berg K, Moan J, Kongshaug M and Nesland JM: 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol 65: 235-251, 1997.
47. Lofgren LA, Ronn AM, Nouri M, Lee CJ, Yoo D and Steinberg BM: Efficacy of intravenous delta-aminolevulinic acid photodynamic therapy on rabbit papillomas. Br J Cancer 72: 857-864, 1995.
48. Gaullier JM, Berg K, Peng Q, Anholt H, Selbo PK, Ma LW and Moan J: Use of 5-aminolevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res 57: 1481-1486, 1997.
49. Brasseur N, Menard I, Forget A, El Jastimi R, Hamel R, Molfino NA and van Lier JE: Eradication of multiple myeloma and breast cancer cells by TH9402-mediated photodynamic therapy: implication for clinical ex vivo purging of autologous stem cell transplants. Photochem Photobiol 72: 780-787, 2000.
50. Daziano JP, Humeau L, Henry M, Mannoni P, Chanon M, Chabannon C and Julliard M: Preferential photoinactivation of leukemia cells by aluminum phthalocyanine. J Photochem Photobiol B Biol 43: 128-135, 1998.
51. Keller GS, Doiron DR and Fisher GU: Photodynamic therapy in otolaryngology-head and neck surgery. Arch Otolaryngol 111: 758-761, 1985.
52. Zhao FY, Zhang KH, Huang HN, Sun KH, Ling QB and Xu B: Use of hematoporphyrin derivative as a sensitizer for radiotherapy of oral and maxillofacial tumors: a preliminary report. Lasers Med Sci 1: 253-256, 1986.
53. Grossweiner LI, Hill JH and Lobraico RV: Photodynamic therapy of head and neck squamous cell carcinoma: optimal dosimetry and clinical trial. Photochem Photobiol 46: 911-917, 1987.
54. Monnier Ph, Savary M, Fontolliet Ch, Wagnières G, Chatelain A, Cornaz P, Depeursinge Ch and van den Bergh H: Photodetection and photodynamic therapy of 'early' squamous cell carcinomas of the pharynx, oesophagus and tracheobronchial tree. Lasers Med Sci 5: 149-169, 1990.
55. Gluckman JL: Hematoporphyrin photodynamic therapy: is there truly a future in head and neck oncology? Reflections on a 5-year experience. Laryngoscope 101: 36-41, 1991.
56. Grosjean P, Savary JF, Mizeret J, Wagnières G, Woodtli A, Theumann JF, Fontolliet C, van den Bergh H and Monnier P: Photodynamic therapy for cancer of the upper aerodigestive tract using Tetra(m-hydroxyphenyl) chlorin. J Clin Laser Med Surg 14: 281-287, 1996.
57. Savary JF, Monnier P, Fontolliet C, Mizeret J, Wagnières G, Braichotte D and van den Bergh H: Photodynamic therapy for early squamous cell carcinomas of the esophagus, bronchi, and mouth with m-Tetra(hydroxyphenyl)chlorin. Arch Otolaryngol Head Neck Surg 123: 162-168, 1997.
58. Fan KFM, Hopper C, Speight PM, Buonaccorsi G, MacRobert AJ and Bown SG: Photodynamic therapy using 5-aminolevulinic acid for premalignant and malignant lesions of the oral cavity. Cancer 78: 1374-1383, 1996.
59. Biel MA: Photodynamic therapy and the treatment of head and neck neoplasia. Laryngoscope 108: 1259-1268, 1998.
60. Sutedja TG and Postmus PE: Photodynamic therapy in lung cancer. A review. J Photochem Photobiol B Biol 36: 199-204, 1996.
61. Hayata Y, Kato H, Konaka C, Ono J and Takizawa N: Hematoporphyrin derivative and laser photoradiation in the treatment of lung cancer. Chest 81: 269-277, 1982.
62. Konaka C, Okunaka T and Kato H: Combined use of photodynamic therapy and surgery. Ann Thorac Cardiovasc Surg 1: 55-60, 1995.
63. Diaz-Jimenez JP, Martinez-Ballarin JE, Llunell A, Farrero E, Rodriguez A and Castro MJ: Efficacy and safety of photodynamic therapy versus Nd-YAG laser resection in NSCLC with airway obstruction. Eur Respir J 14: 800-805, 1999.
64. Moghissi K, Dixon K, Stringer M, Freeman T, Thorpe A and Brown S: The place of bronchoscopic photodynamic therapy in advanced unresectable lung cancer: experience of 100 cases. Eur J Cardiothorac Surg 15: 1-6, 1999.
65. Furuse K, Fukuoka M, Kato H, Horai T, Kubota K, Kodama N, Kusunoki Y, Takifuji N, Okunaka T and Konaka C: A prospective phase II study on photodynamic therapy with Photofrin II for centrally located early-stage lung cancer. J Clin Oncol 11: 1852-1857, 1993.
66. Nakamura H, Kawasaki N, Hagiwara M, Ogata A and Kato H: Endoscopic evaluation of centrally located early squamous cell carcinoma of the lung. Cancer 91: 1142-1147, 2001.
67. Van Boxem AJM, Westerga J, Venmans BJW, Postmus PE and Sutedja G: Photodynamic therapy, Nd-YAG laser and electrocautery for treating early-stage intraluminal cancer: which to choose? Lung Cancer 31: 31-36, 2001.
68. DeLaney TF, Sindelar WF, Tochner Z, Smith PD, Friauf WS, Thomas G, Dachowski L, Cole JW, Steinberg SM and Glatstein E: Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int J Radiat Oncol Biol Phys 25: 445-457, 1993.
69. Bauer TW, Hahn SM, Spitz FR, Káchur A, Glatstein E and Fraker DL: Preliminary report of photodynamic therapy for intraperitoneal sarcomatosis. Ann Surg Oncol 8: 254-259, 2001.
70. Hendren SK, Hahn SM, Spitz FR, Bauer TW, Rubin SC, Zhu T, Glatstein E and Fraker DL: Phase II trial of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Ann Surg Oncol 8: 65-71, 2001.
71. Taber SW, Fingar VH and Wieman TJ: Photodynamic therapy for palliation of chest wall recurrence in patients with breast cancer. J Surg Oncol 68: 209-214, 1998.
72. Wyss P, Schwarz V, Dobler-Girdziunaite D, Hornung R, Walt H, Degen A and Fehr MK: Photodynamic therapy of locoregional breast cancer recurrences using a hlorin-type photosensitizer. Int J Cancer 93: 720-724, 2001.
73. Kostron H, Obwegeser A and Jakober R: Photodynamic therapy in neurosurgery: a review. J Photochem Photobiol B Biol 36: 157-168, 1996.
74. Zimmermann A, Ritsch-Marte M and Kostron H: mTHPC-mediated photodynamic diagnosis of malignant brain tumors. Photochem Photobiol 74: 611-616, 2001.
75. Pass HI, DeLaney T, Tochner Z, Smith PE, Temeck BK, Pogrebniak HW, Kranda KC, Russo A, Friauf WS, Cole JW, Mitchell JB and Thomas G: Intrapleural photodynamic therapy: results of a phase I trial. Ann Surg Oncol 1: 28-37, 1994.
76. Baas P, Murrer L, Zoetmulder FAN, Stewart FA, Ris HB, van Zandwijk N, Peterse JL and Rutgers EJTh: Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br J Cancer 76: 819-826, 1997.
77. Schouwink H, Rutgers ET, van der Sijp J, Oppelaar H, van Zandwijk N, van Veen R, Burgers S, Stewart FA, Zoetmulder F and Baas P: Intraoperative photodynamic therapy after pleuro-pneumonectomy in patients with malignant pleural mesothelioma. Dose finding and toxicity results. Chest 120: 1167-1174, 2001.
78. Nseyo UO, Shumaker B, Klein EA and Sutherland K: Photodynamic therapy using porfimer sodium as an alternative to cystectomy in patients with refractory transitional cell carcinoma in situ of the bladder. J Urol 160: 39-44, 1998.
79. Waidelich R, Stepp H, Baumgartner R, Weninger E, Hofstetter A and Kriegmair M: Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 165: 1904-1907, 2001.
80. Grönlund-Pakkanen S, Pakkanen TM, Koski E, Talja M, Ala-Opas M and Alhava E: Effect of photodynamic therapy on urinary bladder function: an experimental study with rats. Urol Res 29: 205-209, 2001.
81. McCaughan JS Jr, Guy JT, Hicks W, Laufman L, Nims TA and Walker J: Photodynamic therapy for cutaneous and subcutaneous malignant neoplasms. Arch Surg 124: 211-216, 1989.
82. Jeffes EW, McCullough JL, Weinstein GD, Fergin PE, Nelson JS, Shull TF, Simpson KR, Bukaty LM, Hoffman WL and Fong NL: Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid: a pilot dose ranging study. Arch Dermatol 133: 727-732, 1997.
83. Baas P, Saarnak AE, Oppelaar H, Neering H and Stewart FA: Photodynamic therapy with meta-tetrahydroxyphenylchlorin for basal cell carcinoma: a phase I/II study. Br J Dermatol 145: 75-78, 2001.
84. Hsu MJ and Juliano RL: Interactions of liposomes with the reticuloendothelial system. II: Nonspecific and receptor-mediated uptake of liposomes by mouse peritoneal macrophages. Biochim Biophys Acta 720: 411-419, 1982.
85. Soncin M, Polo L, Reddi E, Jori G, Kenney ME, Cheng G and Rodgers MAJ: Effect of the delivery system on the biodistribution of Ge(IV) octabutoxy-phthalocyanines in tumour-bearing mice. Cancer Lett 89: 101-106, 1995.
86. Jori G, Reddi E, Cozzani I and Tomio L: Controlled targeting of different subcellular sites by porphyrins in tumour-bearing mice. Br J Cancer 53: 615-621, 1986.
87. Reddi E, Zhou C, Biolo R, Menegaldo E and Jori G: Liposome- or LDL-administered Zn(II)-phthalocyanine as a photodynamic agent for tumours. I. Pharmacokinetic properties and photo-therapeutic efficiency. Br J Cancer 61: 407-414, 1990.
88. e6 alone. Biochem Int 26: 445-450, 1992.
89. e6. Cancer Res 55: 1014-1019, 1995.
90. e6 enhances its photosensitizing activity. J Biol Chem 272: 20328-20331, 1997.
91. e6. Int J Cancer 81: 734-740, 1999.
92. Melgert BN, Wartna E, Lebbe C, Albrecht C, Molema G, Poelstra K, Reichen J and Meijer DK: Targeting of naproxen covalently linked to HSA to sinusoidal cell types of the liver. J Drug Target 5: 329-342, 1998.
93. e6 selectively potentiates its photodynamic therapy. Cancer Res 60: 2197-2202, 2000.
94. Suzuki S, Takahashi T, Nakamura S, Koike K, Ariyoshi Y, Takahashi T and Ueda R: Alterations of integrin expression in human lung cancer. Jpn J Cancer Res 84: 168-174, 1993.
95. Allen CM, Sharman WM, La Madeleine C, Weber JM, Langlois R, Ouellet R and Van Lier JE: Photodynamic therapy: tumor targeting with adenoviral proteins. Photochem Photobiol 70: 512-523, 1999.
96. Gagnebin J, Brunori M, Otter M, Juillerat-Jeanneret L, Monnier P and Iggo R: A photosensitizing adenovirus for photodynamic therapy. Gene Ther 6: 1742-1750, 1999.
97. e6 and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. J Control Rel 61: 145-157, 1999.
98. e6 and adriamycin conjugates in combination treatments. Clin Cancer Res 6: 1008-1015, 2000.
99. Westermann P, Glanzmann T, Andrejevic S, Braichotte DR, Forrer M, Wagnières GA, Monnier P, van den Bergh H, Mach JP and Folli S: Long circulating half-life and high tumor selectivity of the photosensitizer meta-tetrahydroxyphenylchlorin conjugated to polyethylene glycol in nude mice grafted with a human colon carcinoma. Int J Cancer 76: 842-850, 1998.
100. Ris HB, Im Hof V, Stewart CM, Mettler D and Altermatt HJ: Endobronchial photodynamic therapy: Comparison of mTHPC and polyethylene glycol-derived mTHPC on human tumor xenografts and tumor-free bronchi of minipigs. Lasers Surg Med 23: 25-32, 1998.
101. Reuther T, Kübler AC, Zillmann U, Flechtenmacher C and Sinn H: Comparison of the in vivo efficiency of Photofrin II-, mTHPC-, mTHPC-PEG- and mTHPCnPEG-mediated PDT in a human xenografted head and neck carcinoma. Lasers Surg Med 29: 314-322, 2001.
102. Rovers JP, Saarnak AE, de Jode M, Sterenborg HJCM, Terpstra OT and Grahn MF: Biodistribution and bioactivity of tetrapegylated meta-tetra(hydroxyphenyl) chlorin compared to native meta-tetra (hydroxyphenyl) chlorin in a rat liver tumor model. Photochem Photobiol 71: 210-217, 2000.
103. Brasseur N, Ouellet R, La Madeleine C and van Lier JE: Water-soluble aluminium phthalocyanine-polymer conjugates for PDT: photodynamic activities and pharmacokinetics in tumour-bearing mice. Br J Cancer 80: 1533-1541, 1999.
104. e6 polymer conjugate increases tumor targeting of photosensitizer. Cancer Res 61: 7155-7162, 2001.
105. Taillefer J, Jones MC, Brasseur N, van Lier JE and Leroux JC: Preparation and characterization of pH-responsive polymeric micelles for the delivery of photosensitizing anticancer drugs. J Pharm Sci 89: 52-62, 2000.
106. Taillefer J, Brasseur N, van Lier JE, Lenaerts V, Le Garrec D and Leroux JC: In-vitro and in-vivo evaluation of pH-responsive polymeric micelles in a photodynamic cancer therapy model. J Pharm Pharmacol 53: 155-166, 2001.
107. Pèlegrin A, Folli S, Buchegger F, Mach JP, Wagnières G and van den Bergh H: Antibody-fluorescein conjugates for photoimmunodiagnosis of human colon carcinoma in nude mice. Cancer 67: 2529-2537, 1991.
108. Folli S, Wagnières G, Pèlegrin A, Calmes JM, Braichotte D, Buchegger F, Chalandon Y, Hardman N, Heusser N, Givel JC, Chapuis G, Châtelain A, van den Bergh H and Mach JP: Immunophotodiagnosis of colon carcinomas in patients injected with fluoresceinated chimeric monoclonal antibodies against carcinoembryonic antigen. Proc Natl Acad Sci USA 89: 7973-7977, 1992.
109. Folli S, Westermann P, Braichotte D, Pèlegrin A, Wagnières G, van den Bergh H and Mach JP: Antibody-indocyanin conjugates for immunodetection of human squamous cell carcinoma in nude mice. Cancer Res 54: 2643-2649, 1994.
110. Gutowski M, Carcenac M, Pourquier D, Larroque C, Saint-Aubert B, Rouanet P and Pèlegrin A: Intraoperative immunophotodetection for radical resection of cancers: Evaluation in an experimental model. Clin Cancer Res 7: 1142-1148, 2001.
111. Mew D, Wat CK, Towers GHN and Levy JG: Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. J Immunol 130: 1473-1477, 1983.
112. Jiang FN, Jiang S, Liu D, Richter A and Levy JG: Development of technology for linking photosensitizers to a model monoclonal antibody. J Immunol Methods 134: 139-149, 1990.
113. Jiang FN, Liu D, Neyndorff H, Chester M, Jiang S and Levy JG: Photodynamic killing of human squamous cell carcinoma cells using a monoclonal antibody-photosensitizer conjugate. J Natl Cancer Inst 83: 1218-1225, 1991.
114. e6 conjugates. Proc Natl Acad Sci USA 83: 8744-8748, 1986.
115. Goff BA, Blake J, Bamberg MP and Hasan T: Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. Br J Cancer 74: 1194-1198, 1996.
116. Hamblin MR, Miller JL and Hasan T: Effect of charge on the interaction of site-specific photoimmunoconjugates with human ovarian cancer cells. Cancer Res 56: 5205-5210, 1996.
117. Molpus KL, Hamblin MR, Rizvi I and Hasan T: Intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates. Gynecol oncol 76: 397-404, 2000.
118. Hamblin MR, Del Governatore M, Rizvi I and Hasan T: Biodistribution of charged 17.1A photoimmunoconjugates in a murine model of hepatic metastasis of colorectal cancer. Br J Cancer 83: 1544-1551, 2000.
119. e6 immunoconjugate. Cancer Res 60: 4200-4205, 2000.
120. Soukos NS, Hamblin MR, Keel S, Fabian RL, Deutsch TF and Hasan T: Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res 61: 4490-4496, 2001.
121. Vrouenraets MB, Visser GWM, Stewart FA, Stigter M, Oppelaar H, Postmus PE, Snow GB and van Dongen GAMS: Development of meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy. Cancer Res 59: 1505-1513, 1999.
122. Vrouenraets MB, Visser GWM, Loup C, Meunier B, Stigter M, Oppelaar H, Stewart FA, Snow GB and van Dongen GAMS: Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: a new possibility for use in photodynamic therapy. Int J Cancer 88: 108-114, 2000.
123. Vrouenraets MB, Visser GWM, Stigter M, Oppelaar H, Snow GB and van Dongen GAMS: Targeting of aluminum (III) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: improved efficacy in photodynamic therapy. Cancer Res 61: 1970-1975, 2001.
124. Vrouenraets MB, Visser GWM, Stigter M, Oppelaar H, Snow GB and van Dongen GAMS: Comparison of aluminium (III) phthalocyanine tetrasulfonate- and meta-tetrahydroxyphenyl-chlorin-monoclonal antibody conjugates for their efficacy in photodynamic therapy in vitro. Int J Cancer 98: 793-798, 2002.
125. Carcenac M, Larroque C, Langlois R, van Lier JE, Artus JC and Pèlegrin A: Preparation, phototoxicity and biodistribution studies of anti-carcinoembryonic antigen monoclonal antibody-phthalocyanine conjugates. Photochem Photobiol 70: 930-936, 1999.
126. Carcenac M, Dorvillius M, Garambois V, Glaussel F, Larroque C, Langlois R, Hynes NE, van Lier JE and Pèlegrin A: Internalisation enhances photo-induced cytotoxicity of monoclonal antibody-phthalocyanine conjugates. Br J Cancer 85: 1787-1793, 2001.